Subject(s)
Hidradenitis Suppurativa , Humans , Hidradenitis Suppurativa/drug therapy , Retrospective Studies , Male , Aged , Female , Age FactorsSubject(s)
Humans , Female , Young Adult , Acne Vulgaris/therapy , Hepatitis, Autoimmune , Solar Activity , Severity of Illness IndexSubject(s)
Humans , Female , Young Adult , Acne Vulgaris/therapy , Hepatitis, Autoimmune , Solar Activity , Severity of Illness IndexSubject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Psoriasis/drug therapy , Biological Factors , Coronavirus Infections , Pneumonia, Viral , Pandemics , Retrospective Studies , Hospitals, University , Severity of Illness IndexSubject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Psoriasis/drug therapy , Biological Factors , Coronavirus Infections , Pneumonia, Viral , Pandemics , Retrospective Studies , Hospitals, University , Severity of Illness IndexABSTRACT
Antecedentes y objetivo: Los ensayos pivotales de omalizumab en urticaria crónica espontánea (UCE) tienen un periodo de tratamiento de entre 12 y 24 semanas. Sin embargo, muchos pacientes en práctica clínica requieren periodos de tratamiento más prolongados. Por ello el objetivo es presentar un algoritmo de manejo del fármaco. Materiales y métodos: El documento de consenso que detallamos nace de la puesta en común, aceptación, revisión y confrontación de la literatura reciente del grupo de trabajo de UCE "Xarxa d'Urticària Catalana i Balear" (XUrCB). Resultados: Se inicia el tratamiento a dosis autorizada y se ajusta la dosis en intervalos trimestrales en función del Urticaria Activity Score de los últimos 7 días (UAS7) y/o el Urticarial Control Test (UCT). Conclusiones: El algoritmo propuesto pretende servir de guía respecto a cómo ajustar dosis, cómo y cuándo parar el fármaco y el modo de reintroducirlo en casos de recaída
Background and objective: Pivotal trials with omalizumab for treatment of chronic spontaneous urticaria (CSU) are generally run over 12 to 24weeks. However, in clinical practice, many patients need longer treatment. In this article, we present an algorithm for treatment with omalizumab. Material and methods: The consensus document we present is the result of a series of meetings by the CSU working group of "Xarxa d'Urticària Catalana i Balear" (XUrCB) at which data from the recent literature were presented, discussed, compared, and agreed upon. Results: Treatment with omalizumab should be initiated at the authorized dose, and is adjusted at 3-monthly intervals according to the Urticaria Activity Score Over 7 days, the Urticaria Control Test, or both. Conclusions: The algorithm proposed is designed to provide guidance on how to adjust omalizumab doses, how and when to discontinue the drug, and how to reintroduce it in cases of relapse
Subject(s)
Humans , Urticaria/drug therapy , Omalizumab/administration & dosage , Algorithms , Consensus , Dosage/methods , Histamine H1 Antagonists/administration & dosage , Dose-Response Relationship, DrugABSTRACT
Los nevus epidérmicos son hamartomas originados en la epidermis y/o en las estructuras anexiales de la piel que se han clasificado clásicamente partiendo de la morfología. En los últimos años se han descrito variantes nuevas y se han producido avances en el campo de la genética que han permitido caracterizar mejor estas lesiones y comprender su relación con algunas de las manifestaciones extracutáneas a las que se han asociado. En esta primera parte revisaremos los nevus derivados de la epidermis y los síndromes que se han descrito asociados a ellos
Epidermal nevi are hamartomatous lesions derived from the epidermis and/or adnexal structures of the skin; they have traditionally been classified according to their morphology. New variants have been described in recent years and advances in genetics have contributed to better characterization of these lesions and an improved understanding of their relationship with certain extracutaneous manifestations. In the first part of this review article, we will look at nevi derived specifically from the epidermis and associated syndromes
Subject(s)
Humans , Nevus/epidemiology , Skin/pathology , Hamartoma Syndrome, Multiple , Skin Neoplasms/epidemiology , Nevus/pathology , Nevus/classification , Nevus/geneticsABSTRACT
Los nevus epidérmicos son hamartomas originados en la epidermis y/o en las estructuras anexiales de la piel que se han clasificado clásicamente partiendo de la morfología. En los últimos años se han descrito variantes nuevas y se han producido avances en el campo de la genética que han permitido caracterizar mejor estas lesiones y comprender su relación con algunas de las manifestaciones extracutáneas a las que se han asociado. En esta segunda parte revisaremos los nevus derivados de estructuras anexiales de la piel y los síndromes que se asocian
Epidermal nevi are hamartomatous lesions derived from the epidermis and/or adnexal structures of the skin; they have traditionally been classified according to their morphology. New variants have been described in recent years and advances in genetics have contributed to better characterization of these lesions and an improved understanding of their relationship with certain extracutaneous manifestations. In the second part of this review article, we will look at nevi derived from the adnexal structures of the skin and associated syndromes
Subject(s)
Humans , Nevus/epidemiology , Epidermis/pathology , Nevus, Sebaceous of Jadassohn/pathology , Sebaceous Glands/pathology , Carcinoma, Basal Cell/complications , Nevus/pathology , Hair Follicle/pathology , Sweat Gland Neoplasms/pathology , Skin Neoplasms/pathologyABSTRACT
BACKGROUND AND OBJECTIVE: Pivotal trials with omalizumab for treatment of chronic spontaneous urticaria (CSU) are generally run over 12 to 24weeks. However, in clinical practice, many patients need longer treatment. In this article, we present an algorithm for treatment with omalizumab. MATERIAL AND METHODS: The consensus document we present is the result of a series of meetings by the CSU working group of "Xarxa d'Urticària Catalana i Balear" (XUrCB) at which data from the recent literature were presented, discussed, compared, and agreed upon. RESULTS: Treatment with omalizumab should be initiated at the authorized dose, and is adjusted at 3-monthly intervals according to the Urticaria Activity Score Over 7days, the Urticaria Control Test, or both. CONCLUSIONS: The algorithm proposed is designed to provide guidance on how to adjust omalizumab doses, how and when to discontinue the drug, and how to reintroduce it in cases of relapse.
Subject(s)
Algorithms , Anti-Allergic Agents/therapeutic use , Omalizumab/therapeutic use , Urticaria/drug therapy , Anti-Allergic Agents/administration & dosage , Chronic Disease , Humans , Omalizumab/administration & dosageABSTRACT
Epidermal nevi are hamartomatous lesions derived from the epidermis and/or adnexal structures of the skin; they have traditionally been classified according to their morphology. New variants have been described in recent years and advances in genetics have contributed to better characterization of these lesions and an improved understanding of their relationship with certain extracutaneous manifestations. In the first part of this review article, we will look at nevi derived specifically from the epidermis and associated syndromes.
Subject(s)
Epidermis/pathology , Keratinocytes/pathology , Nevus/classification , Skin Neoplasms/classification , Abnormalities, Multiple/classification , Abnormalities, Multiple/genetics , Abnormalities, Multiple/pathology , Darier Disease/classification , Darier Disease/pathology , Genetic Association Studies , Genetic Diseases, X-Linked/classification , Genetic Diseases, X-Linked/genetics , Genetic Diseases, X-Linked/pathology , Humans , Ichthyosiform Erythroderma, Congenital/classification , Ichthyosiform Erythroderma, Congenital/genetics , Ichthyosiform Erythroderma, Congenital/pathology , Limb Deformities, Congenital/classification , Limb Deformities, Congenital/genetics , Limb Deformities, Congenital/pathology , Mosaicism , Mutation , Nevus/genetics , Nevus/pathology , Pemphigus, Benign Familial/classification , Pemphigus, Benign Familial/pathology , Proteus Syndrome/classification , Proteus Syndrome/genetics , Proteus Syndrome/pathology , Skin Neoplasms/genetics , Skin Neoplasms/pathology , SyndromeABSTRACT
Epidermal nevi are hamartomatous lesions derived from the epidermis and/or adnexal structures of the skin; they have traditionally been classified according to their morphology. New variants have been described in recent years and advances in genetics have contributed to better characterization of these lesions and an improved understanding of their relationship with certain extracutaneous manifestations. In the second part of this review article, we will look at nevi derived from the adnexal structures of the skin and associated syndromes.
